Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 0.73 |
| ▸ | ABL1 | P00519 | 10/20 | 0.73 |
| ▸ | BCR | P11274 | 7/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | KIT | P10721 | 6/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | ABL2 | P42684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040065 | 0.90 | PDGFRA (0.75) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL9971 | 0.85 | ABL1 (0.57) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL3061037 | 0.85 | ABL1 (0.78) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL30752396 | 0.85 | ABL1 (0.78) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9782 | 0.84 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL29498750 | 0.84 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4899602 | 0.84 | PDGFRA (0.82) | PDGFRAABL1BCRPDGFRBPRKCA | |
| Methane SCHEMBL5972158 | 0.83 | PDGFRA (0.98) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL12987337 | 0.83 | PDGFRA (0.63) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL15653665 | 0.82 | PDGFRA (0.62) | PDGFRAABL1BCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470120-A1 | N-OXYDE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2004-10-27 | — | — | EP | claimed |
| WO-2003062220-A1 | N-OXYDE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2003-07-31 | — | — | WO | claimed |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2194049-B1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | BOERNSEN KLAUS OLAF (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | BOERNSEN KLAUS OLAF | 2010-09-02 | — | — | US | disclosed |
| EP-2194049-A1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | BORNSEN KLAUS OLAF | 2009-09-24 | — | — | US | disclosed |
| US-7557105-B2 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2009-07-07 | — | — | US | disclosed |
| EP-1783126-A2 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | NUDT1, NT5C2, NOX5 | PDGFRA 353/4885ABL1 162/4885BCR 4524/4885 |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | NUDT1, PNP, NME2 | PDGFRA 229/4885ABL1 106/4885BCR 4627/4885 |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | MKI67, CDK4, NME2 | PDGFRA 4/4885ABL1 19/4885BCR 1069/4885 |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | PDGFRA 182/4885ABL1 104/4885BCR 4526/4885 |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | PDGFRA 229/4885ABL1 106/4885BCR 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.